MedTrace Logo

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

NCT01609023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2018-06-26

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic lymphocytic leukemia. Data will be collected from eligible participants receiving rituximab according to the Summary of Product Characteristics (SPC) during 6 months of treatment.

Conditions

  • Lymphocytic Leukemia, Chronic

Interventions

DRUG

Rituximab

Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609023 on ClinicalTrials.gov